Analyst On La Jolla's Hypotension Drug: We Expect Approval Next Year
May 22, 2017 at 11:23 AM EDT
Following the publication of full data from a late-stage study of La Jolla Pharmaceutical Company (NASDAQ: LJPC)'s LPJC-501, a ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.